1. Vallianou NG, Geladari E, Kazazis CE. SGLT-2 inhibitors: their pleiotropic properties. Diabetes Metab Syndr. 2017;11(4):311-5. https://doi.org/10.1016/j.dsx.2016.12.003 https://pubmed.ncbi.nlm.nih.gov/28011230 
2. Diabetes Atlas ID. IDF Diabetes Atlas. 8th edition 2017. [cited 2017 Mar 22]. Available from: http://www.diabetesatlas.org/# 
3. Storgaard H, Gluud LL, Bennett C, Grøndahl MF, Christensen MB, Knop FK, et al. Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. PLoS One. 2016;11(11):e0166125. https://doi.org/10.1371/journal.pone.0166125 https://pubmed.ncbi.nlm.nih.gov/27835680 
4. Ivo-Dos-Santos J, Campos DL, Galvão-Castro B. Patterns of serologic response to human immunodeficiency virus type 1 (HIV-1) in Brazilians with different clinical forms of HIV infection. Mem Inst Oswaldo Cruz. 1989;84(1):9-11. https://doi.org/10.1590/S0074-02761989000100003 https://pubmed.ncbi.nlm.nih.gov/2319954 
5. Kalra S, Singh V, Nagrale D. Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review. Adv Ther. 2016;33(9):1502-18. https://doi.org/10.1007/s12325-016-0379-5 https://pubmed.ncbi.nlm.nih.gov/27423646 
6. Kalra S. Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology. Diabetes Ther. 2014;5(2):355-66. https://doi.org/10.1007/s13300-014-0089-4 https://pubmed.ncbi.nlm.nih.gov/25424969 
7. Lioudaki E, Androulakis ES, Whyte M, Stylianou KG, Daphnis EK, Ganotakis ES. The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action. Cardiovasc Drugs Ther. 2017;31(2):215-25. https://doi.org/10.1007/s10557-017-6724-3 https://pubmed.ncbi.nlm.nih.gov/28444472 
8. Martens P, Mathieu C, Verbrugge FH. Promise of SGLT2 Inhibitors in Heart Failure: diabetes and Beyond. Curr Treat Options Cardiovasc Med. 2017;19(3):23. https://doi.org/10.1007/s11936-017-0522-x https://pubmed.ncbi.nlm.nih.gov/28299616 
9. Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2016;374(11):1094. https://pubmed.ncbi.nlm.nih.gov/26981940 
10. Farahani P. Non-severe Hypoglycemia Risk Difference between Sulfonylurea and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2-I) as an Add-On to Metformin in Randomized Controlled Trials. J Popul Ther Clin Pharmacol. 2017;24(2):e32-40. https://doi.org/10.22374/1710-6222.24.2.6 https://pubmed.ncbi.nlm.nih.gov/28594482 
11. Cai X, Yang W, Gao X, Chen Y, Zhou L, Zhang S, et al. The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis. Obesity (Silver Spring). 2018;26(1):70-80. https://doi.org/10.1002/oby.22066 https://pubmed.ncbi.nlm.nih.gov/29165885 
12. Ahmadieh H, Azar S. Effects of Sodium Glucose Cotransporter-2 Inhibitors on Serum Uric Acid in Type 2 Diabetes Mellitus. Diabetes Technol Ther. 2017;19(9):507-12. https://doi.org/10.1089/dia.2017.0070 https://pubmed.ncbi.nlm.nih.gov/28749169 
13. Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. 2016;6(2):e009417. https://doi.org/10.1136/bmjopen-2015-009417 https://pubmed.ncbi.nlm.nih.gov/26911584 
14. Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 2014;13(1):28. https://doi.org/10.1186/1475-2840-13-28 https://pubmed.ncbi.nlm.nih.gov/24475922 
15. Fioretto P, Zambon A, Rossato M, Busetto L, Vettor R. SGLT2 Inhibitors and the Diabetic Kidney. Diabetes Care. 2016;39:S165-71. https://doi.org/10.2337/dcS15-3006 https://pubmed.ncbi.nlm.nih.gov/27440829 
16. Perrone-Filardi P, Avogaro A, Bonora E, Colivicchi F, Fioretto P, Maggioni AP, et al. Mechanisms linking empagliflozin to cardiovascular and renal protection. Int J Cardiol. 2017;241:450-6. https://doi.org/10.1016/j.ijcard.2017.03.089 https://pubmed.ncbi.nlm.nih.gov/28395981 
17. Rastogi A, Bhansali A. SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review. Diabetes Ther. 2017;8(6):1245-51. https://doi.org/10.1007/s13300-017-0320-1 https://pubmed.ncbi.nlm.nih.gov/29076040 
18. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-28. https://doi.org/10.1056/NEJMoa1504720 https://pubmed.ncbi.nlm.nih.gov/26378978 
19. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al.; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-57. https://doi.org/10.1056/NEJMoa1611925 https://pubmed.ncbi.nlm.nih.gov/28605608 
20. Filippatos TD, Tsimihodimos V, Liamis G, Elisaf MS. SGLT2 inhibitors-induced electrolyte abnormalities: an analysis of the associated mechanisms. Diabetes Metab Syndr. 2018;12(1):59-63. https://doi.org/10.1016/j.dsx.2017.08.003 https://pubmed.ncbi.nlm.nih.gov/28826578 
21. Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZ. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. Circulation. 2017;136(17):1643-58. https://doi.org/10.1161/CIRCULATIONAHA.117.030012 https://pubmed.ncbi.nlm.nih.gov/29061576 
22. Rosenstock J, Ferrannini E. Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors. Diabetes Care. 2015;38(9):1638-42. https://doi.org/10.2337/dc15-1380 https://pubmed.ncbi.nlm.nih.gov/26294774 
23. Goldenberg RM, Berard LD, Cheng AY, Gilbert JD, Verma S, Woo VC, et al. SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis. Clin Ther. 2016;38(12):2654-64. https://doi.org/10.1016/j.clinthera.2016.11.002 https://pubmed.ncbi.nlm.nih.gov/28003053 
24. Handelsman Y, Henry RR, Bloomgarden ZT, Dagogo-Jack S, DeFronzo RA, Einhorn D, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of Sglt-2 Inhibitors and Diabetic Ketoacidosis. Endocr Pract. 2016;22(6):753-62. https://doi.org/10.4158/EP161292.PS https://pubmed.ncbi.nlm.nih.gov/27082665 
25. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75(1):33-59. https://doi.org/10.1007/s40265-014-0337-y https://pubmed.ncbi.nlm.nih.gov/25488697 
26. Zaletel J, Ravnik Oblak M, eds. Slovenske smernice za klinično obravnavo sladkorne bolezni tipa 2. 3th ed. Ljubljana: Klinični oddelek za endokrinologijo, diabetes in presnovne bolezni; Interna klinika UKC Ljubljana in Klinični oddelek za endokrinologijo, diabetes in bolezni presnove; Pediatrična klinika Ljubljana; 2016. 
